Gina Tomaine on Muck Rack

Gina Tomaine

Philadelphia
As seen in: HMP Global Learning Network, MSN, Cosmopolitan, Substack, VICE, VICE UK, Bustle, The Boston Globe, Good Housekeeping, The Philadelphia Inquirer, Complex and
writer + editor she/her
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gina

Contact Gina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Chestnut Hill home was an ‘amazing deal,’ even with the cost of a new septic system | How I Bought This House

|
By Gina Tomaine
| The Philadelphia Inquirer Verified
The buyers: Rebecca, 43, surgical oncological nurse, and Ryan Taylor, 43, chief financial officer The house: A 3,250-square-foot home in Chestnut Hill with 5 bedrooms and 4½ bathrooms built in 1898. The price: $925,000. Originally listed for $1,100,000. The agent: Jacob Markovitz, Elfant Wissahickon Realtors Rebecca and Ryan Taylor’s home in Chestnut Hill became "an amazing deal" after they negotiated for repairs, the couple said.
Open in Who Shared Issue with article?

Ever forget you have a body? New book Fat Swim wants to remind you

|
By Gina Tomaine
| Dazed Magazine Verified
More often than I’d like, I’ll spend a day hunched over my laptop, ignoring my aching back or my neck, making little Rice Krispies noises when I turn it. I’ll eat standing instead of sitting. I’ll spend hours and hours tuned into a series of smaller and bigger screens instead of my senses. And then, something will happen. I’ll remember I can go for a walk.
Open in Who Shared Issue with article?

FDA Grants Traditional Approval to Encorafenib-Cetuximab Plus Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer

|
By Gina Tomaine
| Oncology Learning Network Verified
On February 24, 2026, the US Food and Drug Administration (FDA) granted traditional approval to encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for the frontline treatment of patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation, as detected by an FDA-authorized test. The agent had previously received accelerated approval in 2024 in combination with cetuximab and mFOLFOX6 for this patient population.
Open in Who Shared View Duplicates (3) Issue with article?
See all 311 licensed articles (355 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified